SYRS Syros Pharmaceuticals Inc.

7.82
-0.69  -8%
Previous Close 8.51
Open 8.45
Price To Book 5.18
Market Cap 331,890,395
Shares 42,441,227
Volume 360,061
Short Ratio
Av. Daily Volume 494,843
Stock charts supplied by TradingView

NewsSee all news

  1. Syros Announces Strategic Priorities and Expected Milestones

    Potential Proof-of-Concept Data for SY-1425 in Combination with Azacitidine in RARA-Positive Relapsed or Refractory AML Patients Expected in Fourth Quarter of 2020 Mature Data for SY-1425 in Combination with

  2. Syros Announces Appointment of Mark Alles to Its Board of Directors

    Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced the appointment of Mark Alles to the Company's Board of Directors. Mr. Alles is a

  3. GBT Secures $150 Million Non-Dilutive Term Loan Financing

    Balance Sheet Strengthened to Support Pipeline Advancement and Oxbryta™ (voxelotor) Commercialization SOUTH SAN FRANCISCO, Calif., Dec. 18, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT)

  4. GBT and Syros Partner to Discover, Develop and Commercialize Novel Therapies for Sickle Cell Disease and Beta Thalassemia

    Collaboration Combines GBT's Therapeutic Area Leadership with Power of Syros' Gene Control Platform to Find New Medicines to Induce Fetal Hemoglobin Syros to Receive $20 Million Upfront, Three Years of Preclinical

  5. Flagship Pioneering Strengthens Leadership With Appointment of Paul Biondi as Executive Partner

    CAMBRIDGE, Mass., Dec. 16, 2019 /PRNewswire/ -- Flagship Pioneering, a unique life sciences innovation enterprise, today announced the appointment of Paul Biondi to the post of Executive Partner. Mr. Biondi most recently

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 AML data due 4Q 2020.
SY-1425 and azaciditine
Acute Myeloid Leukemia / Myelodysplastic Syndrome
Development to be discontinued - noted October 17, 2019.
SY-1365
Solid tumors
Phase 1 trial to be initiated 1Q 2020 with initial safety data due 4Q 2020. Dose escalation data due mid-2021.
SY-5609
Solid tumors

Latest News

  1. Syros Announces Strategic Priorities and Expected Milestones

    Potential Proof-of-Concept Data for SY-1425 in Combination with Azacitidine in RARA-Positive Relapsed or Refractory AML Patients Expected in Fourth Quarter of 2020 Mature Data for SY-1425 in Combination with

  2. Syros Announces Appointment of Mark Alles to Its Board of Directors

    Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced the appointment of Mark Alles to the Company's Board of Directors. Mr. Alles is a

  3. GBT Secures $150 Million Non-Dilutive Term Loan Financing

    Balance Sheet Strengthened to Support Pipeline Advancement and Oxbryta™ (voxelotor) Commercialization SOUTH SAN FRANCISCO, Calif., Dec. 18, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT)

  4. GBT and Syros Partner to Discover, Develop and Commercialize Novel Therapies for Sickle Cell Disease and Beta Thalassemia

    Collaboration Combines GBT's Therapeutic Area Leadership with Power of Syros' Gene Control Platform to Find New Medicines to Induce Fetal Hemoglobin Syros to Receive $20 Million Upfront, Three Years of Preclinical

  5. Flagship Pioneering Strengthens Leadership With Appointment of Paul Biondi as Executive Partner

    CAMBRIDGE, Mass., Dec. 16, 2019 /PRNewswire/ -- Flagship Pioneering, a unique life sciences innovation enterprise, today announced the appointment of Paul Biondi to the post of Executive Partner. Mr. Biondi most recently

  6. Flagship Pioneering Unveils Cellarity, the First Company to Discover Medicines Targeting Cell Behavior

    CAMBRIDGE, Mass., Dec. 10, 2019 /PRNewswire/ -- Flagship Pioneering, a unique life sciences innovation enterprise, unveiled Cellarity, a first-of-its-kind therapeutics company that is discovering and developing medicines

  7. Syros Presents on Identification of Novel Fetal Hemoglobin Repressor as Part of Broader Drug Discovery Program in Sickle Cell Disease at 61st Annual ASH Meeting

    Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it has discovered and validated a novel fetal hemoglobin repressor, Nuclear Factor

  8. Flagship Pioneering Names Dr. Nancy Simonian, CEO of Syros, as Recipient of the 2019 Pioneering Leader Award

    CAMBRIDGE, Mass., Dec. 2, 2019 /PRNewswire/ -- Flagship Pioneering has announced the recipient of the firm's annual Pioneering Leader Award. The 2019 award recognizes Nancy Simonian, M.D., CEO of Syros

  9. Syros to Present at Piper Jaffray 31st Annual Healthcare Conference

    Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a fireside

  10. Syros to Present on Core Drivers of Metastasis in Triple Negative Breast Cancer at San Antonio Breast Cancer Symposium

    Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that the company and its collaborators from the Whitehead Institute for Biomedical

  11. Syros Reports Third Quarter 2019 Financial Results and Highlights Key Accomplishments and Upcoming Milestones

    Presented New Clinical Data from Phase 2 Study of SY-1425 in RARA-Positive Newly Diagnosed Unfit AML Patients at ESH Conference Presented New Preclinical Data on SY-5609 at AACR-NCI-EORTC Conference On Track for

  12. Syros to Present on Sickle Cell Disease Research at 61st Annual ASH Meeting

    Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will present on its identification and validation of a novel fetal hemoglobin

  13. Syros to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019

    Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Tuesday,

  14. Syros Presents New Preclinical Data on SY-5609, Its Highly Selective Oral CDK7 Inhibitor, at AACR-NCI-EORTC International Conference

    SY-5609 Shows Robust Anti-Tumor Activity in Lung, Breast and Ovarian Cancer Models Deeper and More Sustained Responses Associated with RB Pathway Alterations Preclinical Data Support Planned Clinical Trial Strategy

  15. Syros Announces New Data from Phase 2 Trial of SY-1425 in Combination with Azacitidine Demonstrating High Response Rates, Rapid Onset of Action and Favorable Tolerability Profile in RARA-Positive Newly Diagnosed Unfit AML Patients

    62% Composite Complete Response Rate, with 82% of Patients Achieving or Maintaining Transfusion Independence Data Support RARA as the Optimal Predictive Biomarker for Patient Selection Syros Pharmaceuticals

  16. Syros Announces Update on Selective CDK7 Inhibitor Portfolio

    Prioritizing Development of SY-5609, Its Oral CDK7 Inhibitor, and Discontinuing Further Development of SY-1365, Its Intravenous CDK7 Inhibitor Expects to Initiate Phase 1 Trial of SY-5609 in First Quarter of

  17. Flagship Pioneering Unveils Cygnal Therapeutics

    CAMBRIDGE, Mass., Oct. 8, 2019 /PRNewswire/ -- Flagship Pioneering, a unique life sciences innovation enterprise, today unveiled Cygnal Therapeutics. Founded in 2017 in Flagship Labs, Flagship's innovation foundry,

  18. Flagship Pioneering Unveils Omega Therapeutics and Appoints Seasoned BioPharma Executive Mahesh Karande as President and Chief Executive Officer

    Omega Therapeutics is unleashing the human genome's native capacity to regulate genes and cure disease for a new era of genomic medicine The Company's platform is focused on precise tuning of Insulated Genomic